Compare MXC & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | MXC | MDXH |
|---|---|---|
| Founded | 1972 | 2003 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | |
| Sector | Energy | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.6M | 21.1M |
| IPO Year | 1995 | 2021 |
| Metric | MXC | MDXH |
|---|---|---|
| Price | $9.45 | $0.46 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.67 |
| AVG Volume (30 Days) | 10.5K | ★ 228.8K |
| Earning Date | 02-10-2026 | 05-14-2026 |
| Dividend Yield | ★ 1.02% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.24 | N/A |
| Revenue | ★ $2,705,235.00 | N/A |
| Revenue This Year | N/A | $30.78 |
| Revenue Next Year | N/A | $18.31 |
| P/E Ratio | $39.35 | ★ N/A |
| Revenue Growth | ★ 7.12 | N/A |
| 52 Week Low | $7.16 | $0.40 |
| 52 Week High | $16.48 | $5.33 |
| Indicator | MXC | MDXH |
|---|---|---|
| Relative Strength Index (RSI) | 59.31 | 52.68 |
| Support Level | $8.65 | $0.40 |
| Resistance Level | $9.59 | $3.79 |
| Average True Range (ATR) | 0.45 | 0.03 |
| MACD | 0.05 | 0.02 |
| Stochastic Oscillator | 54.16 | 87.60 |
Mexco Energy Corporation is an independent oil and gas company. It is engaged in the acquisition, exploration, development, and production of natural gas and crude oil properties located in the United States. The company carried out its operation in the Permian Basin of West Texas. It is focusing on two primary areas, the Delaware Basin located in the Western portion of the Permian Basin including Lea and Eddy Counties, New Mexico and Loving County, Texas, and the Midland Basin located in the Eastern portion of the Permian Basin including Reagan, Upton, Midland, Martin, Howard, and Glasscock Counties, Texas. The company generates revenue from Oil sales, Natural gas sales, oil and gas royalty interests.
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.